Hypercholesterolemia study: VERVE-201
Official title Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
ClinicalTrials.gov ID: NCT06451770
What this study is testing
What is VERVE-201?
an investigational IV infusion being studied as a potential treatment for refractory hyperlipidemia (high cholesterol). is designed to use base‑editing technology to inactivate the ANGPTL3 gene in the liver, which may lower LDL‑C and triglycerides.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see if VERVE-201 is safe and how it changes cholesterol and triglyceride levels in these patients.
- Who it's for
- Adults with refractory hyperlipidemia (high LDL‑C or triglycerides that have not responded to other treatments).
- What's involved
- Participants will receive one open‑label dose of VERVE-201 and have regular blood tests and safety check‑ups to monitor their response.
- Time commitment
- The trial lasts a few weeks, with the dosing visit and several follow‑up visits for safety assessments.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Refractory hypercholesterolemia
- Refractory hypertriglyceridemia
You likely can't join if
- Active or history of chronic liver disease
- Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
The study team makes the final eligibility decision.
Where it is enrolling
- Garden Grove, California, United States
- Clearwater, Florida, United States
- Miami Lakes, Florida, United States
- Port Orange, Florida, United States
- New York, New York, United States
- Adelaide, Australia
- Melbourne, Australia
- Chicoutimi, Canada
- Montreal, Canada
- Toronto, Canada
- Amsterdam, Netherlands
- Rotterdam, Netherlands
- Cape Town, South Africa
- Johannesburg, South Africa
- Liverpool, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Garden Grove, California, United States; Clearwater, Florida, United States; Miami Lakes, Florida, United States; Port Orange, Florida, United States; New York, New York, United States; Adelaide, Australia and 11 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.